Citations

Clear

9383 citation(s) found for "Thomas, PS".

Surgeon Sex and Postoperative Resource Utilization: A Population-Based Cohort Study
Satkunasivam, Raj , Aminoltejari, Khatereh, Thomas, Hannah S. , Salles, Arghavan , Coburn, Natalie, Wright, Frances C. , McCartney, Colin J. L. , Armstrong, Kathleen , Bass, Barbara L. , Detsky, Allan S. , Riveros, Carlos , Heybati, Kiyan , Coburn, Natalie, Conn, Lesley Gotlib , Luckenbaugh, Amy N. , Ranganathan, Sanjana , Riveros, Carlos , Sutherland, Jason Murray , Jerath, Angela , Wallis, Christopher J D

Mayo Clinic

Annals of Surgery Open | May 2, 2025 | Volume: 6 | Issue: 2 | Pages: e569

10.1097/as9.0000000000000569 | PMID 40557345 Get It

Objectives: To determine associations between physician sex and use of postoperative healthcare resources among patients undergoing common surgeries in Ontario, Canada. Background: Prior studies have shown that patients of female physicians experience better outcomes and have lower healthcare costs compared with patients of male physicians. Understanding differences in resource utilization may offer insights into the care pathways and practice patterns contributing to these differences. Methods: We conducted a population-based, retrospective cohort study of adults (≥18 years of age) undergoing 1 of 25 common surgeries, between January 1, 2007, and December 31, 2019, in Ontario, Canada. The primary outcome was the utilization of one of the following: intensive care unit admission, other medical interventions (eg, tracheostomy, new dialysis starts, and home oxygen), and discharge care needs (eg inpatient rehab, long-term care, and home care use) within 30 days. The data were summarized using descriptive statistics and adjusted using multivariable generalized estimating equations. Results: This population-based study included 1,100,193 patients (61.8% female). Patients treated by male surgeons had higher use of postoperative resources versus those with female surgeons within 30 days (adjusted rate 33.1; 95% confidence interval [CI]: 28.0–39.2 versus 31.2; 95% CI: 25.8–37.7), 90 days, and 1 year. Consistent with these findings, following adjustment for patient, surgeon, procedural, and hospital characteristics, patients treated by male surgeons were significantly more likely to utilize postoperative resources within 30 days (adjusted odds ratio: 1.14; 95% CI: 1.03–1.27; P = 0.010) and at other time points. This difference was primarily driven by the higher use of home care among patients with a male versus female surgeon at all time points (30 days: adjusted odds ratio, 1.13; 95% CI: 1.05–1.21; P = 0.002). Conclusions: Patients with male surgeons had higher postoperative resource utilization when compared with those treated by female surgeons, which was almost entirely driven by the higher use of home care. Further mixed-methods investigation is needed to better understand other potentially relevant factors including surgical outcomes, individual patient preferences, and surgical team decision-making.
A Novel Presentation and Variable Phenotypic Spectrum of Homozygous Start‐Loss Variant in LYRM7‐Associated Mitochondrial Complex III Deficiency
Luke, Noel Deep , Nair, Aditya , Sivadasan, Ajith , Thomas, Maya , Yoganathan, Sangeetha , Aaron, Rekha , Jasper, Anitha , Mannam, Pavithra , Daniel, Roshan , Aaron, Rekha , Daniel, Roshan , Danda, Sumita , Muthusamy, Karthik

Mayo Clinic

American Journal of Medical Genetics Part A | May 2, 2025 | Volume: 197 | Issue: 9 | Pages: No page available

10.1002/ajmg.a.64105 | PMID 40317892 Get It

ABSTRACT LYRM7‐associated mitochondrial complex III deficiency has classically been described in the literature as a childhood‐onset episodic leukoencephalopathy with neuroimaging findings of cavitating periventricular and subcortical white matter loss. We describe the heterogeneous clinical and neuroimaging profile of six individuals from south India with the specific homozygous pathogenic variant in the LYRM7 gene (c.2T>C, (p.Met1?)). This is a retrospective case series featuring six cases (four pediatric, one adult, and one adolescent‐onset) with the pathogenic start loss LYRM7 variant. The spectrum of neurologic manifestations and brain imaging findings documented over multiple clinic visits was analyzed and described. Vision loss and lactic acidosis were seen in all but one individual. A novel phenotype with adult‐onset isolated bilateral simultaneous optic neuropathy was noted. Characteristic cavitating leukoencephalopathy in supratentorial white matter was seen in the brain MRI of three out of six individuals. A comprehensive description of our cases along with the previously published cases is provided in the table highlighting the clinical and imaging variability and the disease course. The phenotype of adult‐onset isolated acute optic neuropathy can be a manifestation of LYRM7‐related mitochondrial disorder. LYRM7‐associated Mitochondrial Complex III deficiency should be considered in the differential diagnosis of para‐ and post‐infectious demyelinating/inflammatory disorders, especially if there is a background of variable developmental delay, recurrence of the episodes, family history, cystic changes in cerebral white matter on imaging, or poor response to immunomodulation. The case series also exemplifies the intra‐and inter‐familial variability seen with this rare disorder.
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
Wang, Michael , Song, Yuqin, Jurczak, Wojciech, Kahl, Brad S. , Chu, Michael P., Kryachok, Iryna, Fogliatto, Laura, Cheah, Chan Y. , Morawska, Marta , Li, Yufu, Patti, Caterina , Forsyth, Cecily , Lesley, Robin, Ramadan, Safaa, Rule, Simon, Dreyling, Martin , investigators, for the ECHO, Cazap, Nicolás, Foncuberta, María Cecilia, Garate, Gonzalo, Gustavo, Jarchum, Pavlovsky, Miguel Arturo , Riveros, Dardo, Baker, Ross, Butler, Jason, Cannell, Paul , Cheah, Chan, Forsyth, Cecily, Giri, Pratyush, Johnston, Amanda, Lee, Denise , Lee, Hui‐Peng, Mapp, Sally, Roncolato, Fernando , Thant, Aung , Walker, Patricia, Doo, Nicole Wong, Demuynck, Hilde, Offner, Fritz , Hende, Vanessa Van, Vergote, Vibeke, Wu, Ka Lung , Chiattone, Carlos, Azevedo, Sergio de, Fogliatto, Laura, Fonseca, Ana, Hamerschlak, Nelson, Lazaretti, Nicolas, Rocha, Vanderson, Salvino, Marco, Santucci, Rodrigo, Schaan, Mariza, Scheliga, Adriana, Vieira, Garles Miller, Berinstein, Neil, Boutin, Mélina , Chu, Michael, Keating, Mary‐Margaret, Schattner, Ariah, Restrepo, Diego Villa, Cen, Xinan, Du, Xin, Feng, Ru, Gao, Sujun, Huang, Haiwen, Ji, Jie, Jin, Jie, Ke, Xiaoyan, Li, Dengju, Li, Fei, Li, Jianyong, Li, Junmin, Li, Yan, Li, Yufu, Li, Zhenyu, Lin, Li'e, Liu, Tingbo, Lv, Fangfang , Shuang, Yuerong, Sun, Lan, Sun, Xiuhua, Wang, Zhao, Wu, Huijing, Xi, Yaming, Xia, Ruixiang, Xue, Hongwei, Yang, Haiyan, Yi, Shuhua, Zhang, Cheng, Zhang, Huilai, Zhang, Mingzhi, Zhang, Qingyuan, Zhao, Xielan, Zhou, Hui, Hajek, Roman, Jindra, Pavel , Mayer, Jiri, Novak, Jan, Abraham, Julie, Bijou, Fontanet, Bouabdallah, Kamal , Cymbalista, Florence, Guilbert, Sophie, Laribi, Kamel, Rodon, Philippe, Decker, Thomas, Dreger, Peter, Dreyling, Martin, Hess, Georg, Lenz, Georg, Stilgenbauer, Stephan, Tummes, Dirk, Anargyrou, Konstantinos , Dimopoulos, Meletios-Athanassios, Kapsali, Eleni, Kyriakou, Despoina, Panayiotidis, Panayiotis, Pappa, Vasiliki , Stavroyianni, Niki, Cheng, Hoi Ching, Kwong, Yok-Lam, Lee, Harold, Ng, Ting Ying, Wong, Raymond, Borbényi, Zita , Illés, Árpád, Lázár, Zsolt, Nagy, Ágnes , Nagy, Zsolt, Schneider, Tamas, Avivi, Irit, Gurion, Ronit, Horowitz, Netanel, Ronson, Aaron, Arcaini, Luca, Boccomini, Carola, Ghia, Paolo, Luminari, Stefano, Plenteda, Caterina, Santoro, Armando, Zilioli, Vittorio Ruggero, Zinzani, Pier Luigi, Choi, Ilseung , Ennishi, Daisuke , Ichikawa, Satoshi, Ishikawa, Takayuki, Izutsu, Koji, Kato, Koji, Maruyama, Dai, Nagai, Hirokazu, Ota, Shuichi, Saito, Toko, Sakai, Rika, Suzuki, Ritsuro, Uoshima, Nobuhiko , Yano, Takahiro, Yoshida, Isao, Eom, Ki-Seong, Kim, Jin Seok, Kim, Seok Jin, Lee, Jung-Hee, Mun, Yeung Chul, Yoon, Sung Soo , Arreguin, Elsa Veronica Avila, Andrade, Adriana Dominguez, Almaguer, David Gómez, Vera, Maria Silvia Rivas, Anaya, Luis Solís, Berkahn, Leanne, Pemberton, Lucy, Simpson, David, Beltrán, Brady, Quintana, Shirely, Revilla, Jose Carlos, Vargas, Ernesto, Grosicki, Sebastian , Hałka, Janusz , Jedrzejczak, Wieslaw, Knopińska-Posłuszny, Wanda, Krzanowski, Jacek, Lech-Maranda, Ewa, Robak, Tadeusz, Rzepecki, Piotr , Wróbel, Tomasz, Borsaru, Gabriela, Ciuleanu, Tudor Eliade, Danaı̈la, Catalin, Lazaroiu, Mihaela, Alexeeva, Julia, Chistyakov, Valeriy, Manikhas, Georgy, Mikhailova, Natalia, Proydakov, Andrey, Volodicheva, Elena , Voloshin, Sergey, Bastos, Mariana, Cordoba, Raul, Codina, José , Gonzalez, Eva Maria, Marin, Ana, Panizo, Carlos, Rodriguez, Guillermo, Salar, Antonio, Sancho, Juan-Manuel, Velo, Jose A, Chiu, Chang-Fang, Hsiao, Liang-Tsai, Kuo, Ching-Yuan, Lin, Tung-Liang, Lysa, Tamila, Maslyak, Zvenyslava, Nogaieva, Larysa, Polenkov, Sergey, Usenko, Ganna, Agajanian, Richie, Anz, Bertrand, Chaudhry, Arvind, Chiu, Alden , Cultrera, Jennifer, D’Olimpio, James, Dunleavy, Kieron, Fanning, Suzanne, Flinn, Ian, Gabrail, Nashat, Gallinson, David, Goldenberg, Alec, Graf, Solomon, Grover, N., Hess, Brian, Hoffman, Marc, Isufi, Iris, Kahl, Brad, Kambhampati, Suman , Kirkel, Dean, Diaz, Guillermo Lazo, Levy, Moshe, Liu, Delong, Mead, Monica , Paludo, Jonas, Patel, Anjan, Peles, Shachar, Persky, Daniel, Portell, Craig, Rosenthal, Allison, Sano, Dahlia , Smith, Sonali , Smith, Stephen, Spurgeon, Stephen, Tache, Jason, Tsai, Michaela, Veltri, Lauren, Wang, Michael, Yimer, Habte, Bach, Quoc Khanh, Đỗ, Huyền Nga, Luu, Hung Vu, Khoa, Trọng, Phạm, Như Hiệp, Panizo, Carlos , Kriachok, Iryna , Kahl, Brad S , Paludo, Jonas , Cheah, Chan Yoon , Morawska, Marta , Sancho, Juan-Manuel , Forsyth, Cecily , Dreyling, Martin , Belada, David , Song, Yuqin , Paludo, Jonas , Fogliatto, Laura , Zhang, Jingyang , Lesley, Robin, Ramadan, Safaa Mahmoud , Garate, Gonzalo, Riveros, Dardo Alberto, Cannell, Paul , Cochrane, Tara , Giri, Pratyush, Mapp, Sally , Doo, Nicole Wong , Demuynck, H, Hende, Vanessa Van, Vergote, Vibeke K. J. , CHIATTONE, CARLOS SÉRGIO , Farias, João Samuel de Holanda , Fonseca, Ana Rita Da , Rocha, Vanderson , Oliveira, José Salvador Rodrigues de , Scheinberg, Phillip , Scheliga, Adriana , Vieira, Garles Miller Matias , Berinstein, Neil Lorne , Shuang, Yuerong , Hájek, Roman , Mayer, Jiřı́ , Bijou, Fontanet , Cymbalista, Florence, Delwail, Vincent , Genet, Philippe , Dreger, Peter , Heß, Georg , Lenz, Georg , Stilgenbauer, Stephan , Kapsali, Eleni , Katodritou, Eirini , Kyriakou, Despoina S, Panayiotidis, Panayiotis G. , Symeonidis, Argiris , Schneider, Tamas J., Avivi, Irit, Gurion, Ronit , Horowitz, Netanel A. , Arcaini, Luca , Boccomini, Carola , Luminari, Stefano , Santoro, Armando, Zilioli, Vittorio Ruggero , Zinzani, Pier Luigi , Fukushima, Kentaro , Izutsu, Koji , Maruyama, Dai , Tatetsu, Hiro , Kim, Sang‐A , Oh, Sung Yong , Arreguin, Elsa Ávila, Gómez‐Almaguer, David , Issa, Samar , Revilla, Jose C., Vargas, Ernesto, Lech-Maranda, Ewa, Robak, Tadeusz , Borsaru, Gabriela, Ciuleanu, Tudor–Eliade , Danaila, Catalin-Doru , Alexeeva, Julia, Briones, Javier , Salar, Antonio , Yuste, Victor Jimenez, Chen, Chien‐Yuan , Kuo, Ching‐Yuan, Anz, Bertrand, Cultrera, Jennifer L. , D’Olimpio, James, Dunleavy, Kieron , Gabrail, Nashat , Gallinson, David, Goldenberg, Alec S., Goy, Andre Henri , Graf, Solomon A. , Hess, Brian, Kirkel, Dean, Portell, Craig A. , Rosenthal, Allison , Stevens, Don, Veltri, Lauren Westfall , Yimer, Habte, Tran, Thanh Tung

Mayo Clinic

Journal of Clinical Oncology | May 1, 2025 | Volume: 43 | Issue: 20 | Pages: 2276-2284

10.1200/jco-25-00690 | PMID 40311141 Get It

PURPOSE The combination of the Bruton tyrosine kinase inhibitor ibrutinib with bendamustine-rituximab for first-line treatment of mantle cell lymphoma (MCL) prolonged progression-free survival (PFS), but without improvement in overall survival (OS), likely because of toxicity. Acalabrutinib was shown to be efficacious and less toxic than ibrutinib in a head-to-head trial in chronic lymphocytic leukemia and therefore might lead to better outcomes in MCL. METHODS Patients 65 years and older with previously untreated MCL received acalabrutinib (100 mg twice daily) or placebo (until disease progression or unacceptable toxicity), plus six cycles of bendamustine (90 mg/m 2 once daily; days 1 and 2) and rituximab (375 mg/m 2 as a single dose; day 1) followed by rituximab maintenance in responding patients for 2 years. Crossover to acalabrutinib at disease progression was permitted. The primary end point was PFS per the independent review committee; overall response rate and OS were secondary end points. RESULTS In total, 598 patients were randomly assigned, with 299 in each arm. At a median follow-up of 49.8 months using the reverse Kaplan-Meier method, the median PFS was 66.4 months in the acalabrutinib arm and 49.6 months in the placebo arm (hazard ratio [HR], 0.73 [95% CI, 0.57 to 0.94]; P = .0160). Benefit was seen across all subgroups, including those with high-risk features. Overall response/complete response rates were 91.0%/66.6% and 88.0%/53.5% in the acalabrutinib and placebo arms, respectively. OS was not significantly different (HR, 0.86 [95% CI, 0.65 to 1.13]; P = .27). Grade 3 or greater adverse events were reported in 88.9% and 88.2% in the acalabrutinib and placebo arms, respectively. CONCLUSION The combination of acalabrutinib with bendamustine-rituximab significantly improved PFS. Clinical benefit of acalabrutinib with bendamustine-rituximab was achieved with manageable toxicity.
Can quantitative sensory testing predict treatment outcomes in hip and knee osteoarthritis? A systematic review and meta-analysis of individual participant data
Murphy, Myles , Mosler, A. , Coventry, Molly , Arendt‐Nielsen, Lars , Bjurström, Martin F. , Larsen, Dennis Boye , Olesen, Anne Estrup , Hertel, Emma , Holm, Pætur Mikal , Gomes, Cid André Fidelis de Paula , Drewes, Asbjørn Mohr , Nunes, Guilherme S. , Østerås, Håvard , Öztürk, Özgul , Pozsgai, M. , Rasmussen, Sten , Rice, David A. , Romero, Eleuterio A. Sánchez , Irani, Anushka, Stausholm, Martin Bjørn , Petersen, Kristian Kjær , Irani, Anushka , Murphy, Myles C , Irani, Anushka , Rio, Ebonie , Raj, Isaac Selva , Chivers, Paola , Alfieri, Fábio Marcon , Chang, Wei‐Ju , Graven‐Nielsen, Thomas , Henriksen, Marius , Klinedinst, N. Jennifer , Mathew, Jerin , O’Leary, Helen , Rampazo, Érika Patrícia , Irani, Anushka, Hince, Dana

Mayo Clinic

Pain | May 1, 2025 | Volume: 166 | Issue: 10 | Pages: 2261-2280

10.1097/j.pain.0000000000003627 | PMID 40310871 Get It

Abstract An individual participant data (IPD) meta-analysis can assess the predictive value of data on outcomes at the individual level, offering a potential tool for developing personalized pain management. Pretreatment quantitative sensory testing (QST) may stratify patient groups, which are then linked to treatment outcomes. Our objective was to determine if measures of QST at baseline are related to treatment outcomes (at any time point) for pain and disability in lower-limb osteoarthritis. We performed a systematic review with an IPD meta-analysis. Searches were conducted in 9 databases until May 5, 2023 for intervention studies that measured baseline QST and longitudinal measures of participant-reported pain and disability. We performed a 2-stage approach to analyse longitudinal data. Individual models were fitted to each study and combined using random effects multivariate meta-analytic models. Study quality was assessed using the Joanna Briggs Institute checklist, and certainty of the evidence was assessed using GRADE. We identified 3082 records and included 1 hip and 28 knee datasets consisting of 2522 participants from 40 studies. Local warm detection thresholds (P = 0.024) predicted knee osteoarthritis pain outcomes (very-low certainty). Local warm detection thresholds (P = 0.030), remote cold detection thresholds (P = 0.05), and remote pressure tolerance thresholds (P = 0.007) predicted knee osteoarthritis disability outcomes (very-low certainty). Other QST variables were associated with hip and knee osteoarthritis pain and disability levels (eg, pressure pain thresholds), but this relationship did not change over time. This review finds that mechanism-based, QST methodologies do not consistently predict pain or disability on an individual level in hip or knee osteoarthritis.
HOPE Experience Essentials: The Next Generation of Service Standards at Mayo Clinic
Packard, Jennifer, Welch, Thomas, Munson, Karee, Leighton, Jonathan A. , Packard, Jennifer, Eliáš, Richard

Mayo Clinic

Patient Experience Journal | May 1, 2025 | Volume: 12 | Issue: 1 | Pages: 192-197

10.35680/2372-0247.1907 Get It

Engaging employees in providing exemplary patient experience has been challenging for healthcare leaders in recent years given the pressures of the regulatory environment, increases in staff burnout and rising patient expectations. Amid these challenges, addressing patient experience remains a top priority for healthcare organizations. A novel intervention has been applied at Mayo Clinic with the goal of improving both employee engagement and patient experience. Previous efforts to teach service excellence involved customer service trainings, sometimes purchased through outside vendors. This new initiative is based on our organizational culture and values, input from our employees and patients, and considers the changing needs of a contemporary healthcare workforce. It leverages management practices shown to boost an employee's sense of equity, achievement, and camaraderie. It also highlights staff motivation to do their best work by involving them in conversations about the essential ingredients that make up both exceptional employee and patient experiences.
Higher risk of recurrence in partially thrombosed cerebral aneurysms post-WEB (Woven EndoBridge) device treatment: insights from the WorldWideWEB Consortium registry
Saliou, Guillaume , Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Aslan, Assala , Swaid, Christian, Cuellar, Miguel, Dibas, Mahmoud , Cancelliere, Nicole M , Diestro, Jose Danilo Bengzon , Lay, Sovann V. , Guenego, Adrien , Möhlenbruch, Markus , Kral, Michael , Salem, Mohamed M , Foreman, Paul M. , Shaikh, Hamza , Župančić, Vedran , Rabinov, James D. , Ren, Yifan , Michelozzi, Caterina , Starke, Robert M. , Ogilvie, Mark , Nguyên, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Psychogios, Marios‐Nikos , Ulfert, Christian , Pukenas, Bryan , Burkhardt, Jan Karl, Slawski, Diana , Pulli, Benjamin , Lubicz, Boris , Puri, Ajit S , Pero, Guglielmo , Raz, Eytan , Asadi, Hamed , Siddiqui, Adnan H. , Haranhalli, Neil , Altschul, David , Ducruet, Andrew F. , Albuquerque, Felipe C , Regenhardt, Robert W. , Stapleton, Christopher J. , Kan, Peter , Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Knopman, Jared , Tjoumakaris, Stavropoula , Jabbour, Pascal , Clarençon, Frédéric , Patel, Aman B. , Salim, Hamza , Ghozy, Sherief , Lay, Sovann V , Guenego, Adrien , Carnevale, Joseph Anthony , ElNaamani, Kareem , Shotar, Eimad , Chung, Charlotte , Salem, Mohamed M , Lylyk, Ivan , Shaikh, Hamza A , Hafeez, Muhammad U , Catapano, Joshua S , Ren, Yifan , Schirmer, Clemens M , Michelozzi, Caterina , Hassan, Ameer E , Ogilvie, Mark , Nguyen, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Huynh, Thien J, Martinez-Gutierrez, Juan Carlos , Essibayi, Muhammed Amir , Sheth, Sunil A , Tawk, Rabih G , Pulli, Benjamin , Pero, Guglielmo , Raz, Eytan , Griessenauer, Christoph J , Siddiqui, Adnan H , Levy, Elad I , Albuquerque, Felipe C , Stapleton, Christopher , Kan, Peter , Kalousek, Vladimir , Tjoumakaris, Stavropoula , Cuellar-Saenz, Hugo H , Jabbour, Pascal , Dmytriw, Adam A , Hajdu, Steven D , Dibas, Mahmoud , Diestro, Jose Danilo B , Saliou, Guillaume , Altschul, David J , Musmar, Basel , Regenhardt, Robert W , Cancelliere, Nicole M , Ulfert, Christian , Burkhardt, Jan‐Karl , Cuellar, Miguel, Algin, Oktay , Ghozy, Sherief , Renieri, Leonardo , Mastorakos, Panagiotis , Naamani, Kareem El , Shotar, Eimad , Lylyk, Iván , Hafeez, Muhammad Ubaid , Waqas, Muhammad , Arslan, Muhammet , Ergün, Onur , Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna Luisa , Hassan, Ameer E , Huynh, Thien , Essibayi, Muhammed Amir , Tawk, Rabih G. , Panni, Pietro , Griessenauer, Christoph J. , Levy, Elad I. , Cuellar, Hugo , Limbucci, Nicola , Mendes Pereira, Vitor , Dmytriw, Adam A.

Mayo Clinic

Journal of NeuroInterventional Surgery | April 30, 2025 | Volume: 18 | Issue: 3 | Pages: 782-789

10.1136/jnis-2024-022628 | PMID 40306928 Get It

Background The Woven EndoBridge (WEB) device is a prevalent treatment for intracranial aneurysms. While many studies have assessed the obliteration rate post-WEB embolization, few have focused on long-term outcomes in partially thrombosed aneurysms. Objective To assess whether partially thrombosed aneurysms are at higher risk of recurrence or retreatment following WEB embolization compared with non-thrombosed aneurysms. Methods We evaluated data from 22 academic institutions, focusing on previously untreated cerebral aneurysms treated with the WEB device. Logistic regression was utilized to analyze factors predicting long-term aneurysm obliteration and retreatment necessity. Results Among 1303 patients, 26 presented with a partially thrombosed aneurysm. In the partially thrombosed group, the mean aneurysm maximal diameter was 10.7±4 mm with a neck ratio of 1.99±1.19 mm, larger than in the control group where the mean aneurysm maximal diameter was 6.81±2.37 mm with a neck ratio of 1.64±0.51 mm (P<0.001 for both maximal diameter and neck ratio). At the final follow-up, partially thrombosed aneurysms treated by the WEB device had a 38.5% retreatment rate, compared with 7.0% for non-thrombosed aneurysms (P<0.001). Among partially thrombosed aneurysms, the Raymond-Roy type IIIa/b occlusion rate was higher (38.5% vs 9.9%, P<0.001). On multivariate analysis, partially thrombosed aneurysms compared with non-thrombosed aneurysms had an increased rate of retreatment (OR 3.64, 95% CI 1.28 to 10.1). Conclusion Partially thrombosed aneurysms are associated with a poorer occlusion rate and a higher rate of retreatment following WEB embolization. For partially thrombosed aneurysms, the WEB device appears suboptimal as a first-line treatment, and therefore alternative techniques should be prioritized.
Delirium prevalence, interventions and barriers in intensive care units in German‐speaking countries: A retrospective cross‐sectional secondary analysis
Exl, Matthias Thomas , Fischbacher, Sibylle, Liu, Keibun , Hoffmann, Magdalena , Nydahl, Peter, Haken, Rebecca von , Schimböck, Florian , Group, the WDAD Study, Olotu, Cynthia , Jeitziner, Marie-Madlen , Lindroth, Heidi , Jeitziner, Marie‐Madlen , Nydahl, Peter , Krüger, Lars , Group, the WDAD Study

Mayo Clinic

Nursing in Critical Care | April 28, 2025 | Volume: 30 | Issue: 3 | Pages: No page available

10.1111/nicc.70041 | PMID 40289504 Get It

Abstract Background The prevalence of delirium in intensive care units (ICUs) is high and has a major impact on patient outcomes. Aim To describe delirium assessment instruments, prevalence, interventions and barriers in delirium management in adult and paediatric ICUs; and to explore the association between delirium prevalence and reported interventions and barriers at unit level. Study Design A secondary analysis of the cross‐sectional World Delirium Awareness Day Delirium Survey on 15 March 2023. This was a prospective study to assess the one‐day point delirium prevalence, practices and quality improvement efforts across healthcare systems. Data was analysed descriptively and using multiple linear regression. Results Data of 1612 assessments in 123 ICUs from three German‐speaking countries were analysed. The most frequently used delirium assessment instrument was the Intensive Care Delirium Screening Checklist (43.9%, n = 54). The prevalence of delirium at 8 AM was 18.6% and at 8 PM 20.4% from the 94 ICUs included in the regression analyses. Prevalence for adult and paediatric and mixed ICUs are comparable. Main reported over all unit‐level interventions were ‘pain management’ (95.9%, n = 118), ‘mobilization’ (94.3%, n = 116) and ‘verbal re‐orientation’ (84.6%, n = 104). Main reported over all unit‐level barriers were ‘shortage of staff’ (53.7%, n = 66) and ‘patients who are difficult to assess’ (44.7%, n = 55). Interventions such as ‘avoidance of bladder tubes/catheters’ in all ICUs, ‘use of ear plugs and/or sleep glasses’ in adult ICUs and ‘mobilization’ in paediatric and mixed ICUs were associated with reduced delirium prevalence. Across all ICUs, as well as in both adult and paediatric ICUs, ‘lack of appropriate scores for delirium assessment’ was identified as a significant barrier. Conclusions One fifth of assessed ICU patients suffer from delirium. Several reported unit‐level interventions and barriers may have an impact on delirium prevalence, suggesting an approach for future studies and clinical practice. Relevance to Clinical Practice In clinical practice, unit‐level ‘avoidance of bladder tubes/catheters’, ‘use of ear plugs and/or sleep glasses’ and ‘mobilization’ may be used as delirium prevention and treatment interventions.
Abstract LB082: Disrupting lipid metabolism in GBM: A systems biology approach to targeting treatment-resistant persister cells and tumor associated myeloid cell-mediated support
Chakraborty, Avirup , Yang, Changlin , Feier, Diana , Silver, Aryeh , Searl, Nyla, Anica, Miruna, Pittu, Avinash, West, Illena, Sobanjo, Olusegun O., Hodge, Ethan, Engelbart, Mia, Sengupta, Srabasti, Thomas, Nagheme, Rahman, Maryam, Sarkisian, Matthew R. , Huang, Jianping , Mitchell, Duane A. , Chakraborty, Avirup , Feier, Diana, West, Illena, Sengupta, Srabasti, Roemeling, Christina A. Von , Harrison, Jeffrey K. , Deleyrolle, Loic P.

Mayo Clinic

Cancer Research | April 25, 2025 | Volume: 85 | Issue: 8_Supplement_2 | Pages: LB082-LB082

10.1158/1538-7445.am2025-lb082 Get It

Abstract Introduction: Glioblastoma (GBM) tumors contain distinct cell lineages, including treatment-sensitive cells (TSCs) relying on aerobic glycolysis and treatment-resistant persister cells (TRPCs) dependent on lipid metabolism. Our systems biology-based, spatial multi-omics and multi-targeted approach decodes a critical node in GBM progression, lipid acquisition in TRPCs, and validates this through a retrospective analysis of statin-treated patients, offering clinical insights into the potential benefits of targeting lipid metabolism in high TRPC signature GBM patients. Methods: We performed spatial transcriptomics and proteomics, combined with 3D rendering of the tumor microenvironment (TME) and geospatially resolved single-cell neighborhood analysis of IHC-stained GBM tissues using our custom-developed SNAQ algorithm to investigate the immune microenvironment and lipid distribution specific to TSCs and TRPCs. To characterize lipid dynamics, we employed flow cytometry, time-lapse imaging, and holotomography to track lipid transfer from Tumor-Associated Myeloid Cells (TAMCs) to TRPCs. A critical node for GBM progression was identified through in vivo survival and tumor progression studies that assessed effects of genetic targeting of CCR2 and pharmacological targeting of CSF1R and FABP3. Retrospective analysis was conducted on 4,085 GBM patients to evaluate the effect of statin treatment on GBM outcomes based on their TRPC signature. Results: Our study establishes the skewed accumulation of TAMCs within the TRPC microenvironment through upregulation of the CCL2/7-CCR2 and CSF1-CSF1R pathways. TAMCs actively transfer lipids to TRPCs to fulfill their metabolic demands. Targeting elements responsible for lipid incorporation in TRPCs, such as CCR2, CSF1R, and FABP3 in vivo, resulted in tumor immune microenvironment remodeling, significant tumor growth reduction, and improved survival. This reinforces the critical role of metabolic communications via lipid trafficking in TRPCs as an essential node in GBM progression. Our retrospective study showed that GBM patients with elevated TRPC signatures, typically associated with shorter survival, had no significant survival differences when treated with lipid-lowering statins. This suggests statins may disrupt lipid metabolism in TRPCs, reducing TAMC lipid support and improving patient outcomes. Conclusion: Our study highlights lipid trafficking in TRPCs as a key mechanism in GBM progression, suggesting that targeting TAMC recruitment and lipid acquisition in TRPCs may offer a promising therapy. Additionally, our retrospective analysis highlights the potential of transcriptomic profiling for patient stratification based on TRPC signature expression levels, enabling the identification of patients to benefit from lipid metabolism-targeted therapies. Citation Format: Avirup Chakraborty, Changlin Yang, Diana Feier, Aryeh Silver, Nyla T. Searl, Miruna Anica, Avinash Pittu, Illena West, Olusegun O. Sobanjo, Ethan D. Hodge, Mia K. Engelbart, Srabasti Sengupta, Nagheme Thomas, Christina Von Roemeling, Maryam Rahman, Matthew Sarkisian, Jianping Huang, Jeffrey Harrison, Duane A. Mitchell, Loic P. Deleyrolle. Disrupting lipid metabolism in GBM: A systems biology approach to targeting treatment-resistant persister cells and tumor associated myeloid cell-mediated support [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr LB082.
Abstract CT269: First-in-human trial in patients with metastatic colorectal cancer using CRISPR-engineered tumor infiltrating lymphocytes in which the intracellular immune checkpoint CISH is inhibited
Choudhry, Modassir, Folsom, Timothy D., Rathmann, Blaine, DeFeo, Anthony P. , Kim, Ji Hyun , Sumstad, Darin , Klebanoff, Christopher A. , Ladner, Katherine J., Sarkari, Akshat , McIvor, R. Scott , Rao, Madhuri , Ankeny, Jacob S. , Khalifa, Mahmoud A. , Chauhan, Anil , Dixit, Ajay , Weber, Daniel , Byrne‐Steele, Miranda, Henley, Tom , McKenna, David H. , Johnson, M. J. , Webber, Beau R. , Webber, Beau R , Lou, Emil , Starr, Timothy K. , Bell, Jason B , Slipek, Nicholas J. , Jin, Zhao-Hui , Murray, Thomas A. , Miller, Jeffrey S. , Jensen, Eric Hans , Spilseth, Benjamin , Provenzano, Paolo P. , Pan, Wenjing , Moriarity, Branden S.

Mayo Clinic

Cancer Research | April 25, 2025 | Volume: 85 | Issue: 8_Supplement_2 | Pages: CT269-CT269

10.1158/1538-7445.am2025-ct269 Get It

Abstract Background: Given the dramatic rise in incidence of colorectal cancer in young adults, there remain limited treatment options effective in metastatic disease. Although T cell-based therapies have been successful in treating highly antigenic cancers, like melanoma and lung, they have not yet been shown to induce consistent and durable tumor regression in common epithelial malignancies, including metastatic colorectal cancer (mCRC). CISH (Cytokine inducible SH2 containing protein) is a novel intracellular checkpoint target demonstrating PD-L1 ligand independent mechanisms of enhanced anti-cancer activity. Given that CISH is not currently tractable via antibody or small molecule drug modalities, we employed CRISPR for precise inhibition of CISH in tumor infiltrating lymphocytes (TILs). Here, we provide the first clinical report of safety and anti-tumor activity of CISH edited TILs in 12 patients with metastatic gastrointestinal cancers (NCT04426669), including a clinical complete response (CR) in a young-adult patient with immunotherapy-refractory mCRC. Methods: Tumors were surgically resected for TIL harvest, followed by a rapid expansion protocol and CRISPR/Cas9 knockout (KO) CISH. CISH KO, neoantigen-reactive TILs were expanded, then infused following non-myeloablative lymphocyte depleting (LD) chemotherapy (cyclophosphamide & fludarabine) followed by high-dose IL-2. To establish mechanistic attribution of the CR, we used iR-RepSeq+ for serial analysis of the TCR immune repertoire. Results: Our CRISPR engineering led to KO of CISH in T cells with high-efficiency (&gt;90%) without detectable off-target editing. We safely dosed patients at all five dose levels (range: 1.91e8 to 9.93e10 cells). No dose-limiting toxicities attributable to the CISH-KO TIL product were observed. Adverse events were consistent with established risks of LD chemotherapy, IL-2, or disease progression. A durable ongoing complete response (&gt;21 months) was achieved in a patient with microsatellite instability-high (MSI-H) mCRC refractory to anti-PD1/CTLA-4 combination therapy. Conclusions: We provide the first clinical report of CISH checkpoint targeting via genetically modified T cell therapy, with complete response in a patient with mCRC. Persistence and expansion of unique TCR clonotypes detected in neoantigen responsive TIL was temporally consistent with spikes in CISH edited alleles detected by NGS assay; in the patient with CR, four of the clonotypes exhibiting prolonged persistence greater than one-year post-infusion exhibited significantly reduced or undetectable expression of CISH compared to the total infused TIL population. Given these findings, further investigation of CISH checkpoint inhibition, via gene and cell therapy, and next-generation small molecule drugging modalities, is underway. Citation Format: Emil Lou, Modassir S. Choudhry, Timothy K. Starr, Timothy Folsom, Jason Bell, Blaine Rathmann, Anthony P. DeFeo, Ji Hyun Kim, Nicholas Slipek, Zhaohui Jin, Darin Sumstad, Christopher A. Klebanoff, Katherine Ladner, Akshat Sarkari, R Scott McIvor, Thomas A. Murray, Jeffrey Miller, Madhuri Rao, Eric Jensen, Jacob Ankeny, Mahmoud A. Khalifa, Anil Chauhan, Benjamin Spilseth, Ajay Dixit, Paolo P. Provenzano, Wenjing Pan, Daniel Weber, Miranda Byrne-Steele, Tom Henley, David H. McKenna, Matthew J. Johnson, Beau R. Webber, Branden S. Moriarity. First-in-human trial in patients with metastatic colorectal cancer using CRISPR-engineered tumor infiltrating lymphocytes in which the intracellular immune checkpoint CISH is inhibited [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT269.